Table 5.

Results from logistic regression models of the probability of death during tuberculosis treatment.

	No. of patients	No. of deaths (%)	Model 1 aOR (95% CI)	Model 2 aOR (95% CI)	Model 3 aOR (95% CI)
Concordance / discordance of DST results
Concordance	466	46 (9.9)	1
Discordance potentially leading to under treatment	22	9 (40.9)	7.33 (2.70–19.95)
Discordance potentially leading to over treatment	61	6 (9.8)	0.81 (0.31–2.11)
Other discordance	24	6 (25.0)	4.92 (1.69–14.33)
Drug resistance a
Pan-susceptible	359	23 (6.4)		1
Mono-resistance	39	10 (25.6)		6.05 (2.36–15.56)
MDR	146	24 (16.4)		3.83 (1.88–7.81)
Pre-XDR/XDR	29	10 (34.5)		15.19 (5.45–42.36)
Treatment adequacy by drug resistance
Pan-susceptible, compatible with WHO guidelines	336	20 (6.0)			1
Pan-susceptible, over treatment	23	3 (13.0)			3.31 (0.82–13.45)
Any resistance, compatible with WHO guidelines	200	36 (18.0)			4.66 (2.16–9.14)
Any resistance, under treatment	14	8 (57.1)			19.32 (5.59–66.73)
Sex
Female	219	20 (9.1)	1	1	1
Male	354	47 (13.3)	1.47 (0.81–2.67)	1.42 (0.78–2.60)	1.46 (0.80–2.70)
Age (per 1 year increase)	573	67 (11.7)	1.04 (1.01–1.06)	1.04 (1.01–1.06)	1.04 (1.01–1.06)
Sputum microscopy
Negative	111	10 (9.0)	1	1	1
Positive	462	57 (12.3)	1.14 (0.51–2.56)	1.03 (0.45 −2.37)	0.90 (0.40–2.07)
HIV status
Negative	337	43 (12.8)	1	1	1
Positive	236	24 (10.2)	0.90 (0.50–1.61)	1.19 (0.65–2.20)	1.19 (0.65–2.20)

Models based on 573 patients with complete data for all variables shown (see supplementary Figure S1).

Model 1 was adjusted for concordance / discordance of DST results, sex, age, sputum microscopy and HIV status; model 2 was adjusted for drug resistance, sex, age, sputum microscopy and HIV status; model 3 was adjusted for treatment adequacy, sex, age, sputum microscopy and HIV status.

Abbreviations: DST, drug susceptibility testing; MDR, multidrug resistant; XDR, extensively drug-resistant

^aResults from the Swiss National Reference Center for Mycobacteria